2nd Cell Engager Therapeutics Summit 2020

Memo

The clinical proof of concept and potential of cell engager drugs has led to investments and collaborations exploding in the field of multi-specific cell engaging antibody drugs. The Cell Engager Summit will address the key challenges hindering multi-specific cell engaging drugs from fulfilling their potential and becoming a mainstream cancer therapy.Join industry leaders to: • Assess current limitations of cell engagers to mitigate toxicities and ensure patient safety • Address Half-Life and Cytokine Release Syndrome to Improve the Therapeutic Window: Explore bivalent target engagement and combination therapies • Learn what drugs are currently in pre-clinical and clinical stages of development: Novel clinical data outlining study designs for liquid and solid tumors • Compare the biology of T-cells, NK cells and Gamma Delta cells for use in immune-oncology: Learn from case studies about the advantages and disadvantages of each cell type • Analyze tumor target selection to maximize efficacy whilst minimizing toxicity: Compare platforms, target feasibility and selection • Optimize the next generation of cell engager drug discovery: Through advances in technology to achieve maximum therapeutic response • Compare Cell Engager therapeutics with CAR-T and Bispecifics: Comparing design strategies and benchmarking T Cell-Redirecting Therapies Venue details: Courtyard by Marriott Boston Downtown, 275 Tremont Street, Boston, 02116, United States Time: 9:00 am - 5:00 pm Prices:Industry Pricing - Conference + 2 Workshops: USD 3897.0,Industry Pricing - Conference + 1 Workshop: USD 3498.0,Industry Pricing - Conference Only: USD 2999.0,Industry Pricing - Workshop Only: USD 599.0,Biotech/Academic Pricing - Conference + 2 Workshops: USD 2597.0,Biotech/Academic Pricing - Conference + 1 Workshop: USD 2398.0,Biotech/Academic Pricing - Conference Only: USD 2099.0,Biotech/Academic Pricing - Workshop Only: USD 399.0 Speakers: Julie Bailis, Amgen, Victoria Smith, Amphivena, Volker Schellenberger, Amunix, Eugene Zhukovsky, Biomunex, James Legg, Crescendo Biologics, Jennifer Michaelson, Cullinan Oncology, Steve Arkinstall, Elstar Therapeutics, Brian Rabinovich, EMD Serono, Rick Austin, Harpoon Therapeutics Inc., Holger Wesche, Harpoon Therapeutics Inc., Rajkumar Ganesan, Janssen, Hans van der Vliet, Lava Therapeutics, Jan Davidson, Macrogenics, Paul Moore, MacroGenics, Chad May, Maverick Therapeutics, Cris Kamperschroer, Pfizer, Malgorzata Nocula-Lugowska, Pfizer, Divya Mathur, Pfizer, David DiLillo, Regeneron, Jessica Kirshner, Regeneron Pharmaceuticals, Patricia Giblin, Revitope, Omid Vafa, TeneoBio, Jeffrey Miller, University of Minnesota, Tatiana Novobrantseva, Verseau, John Desjarlais, Xencor